Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
about
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasisThe development of drugs for treatment of sleeping sickness: a historical reviewA current analysis of chemotherapy strategies for the treatment of human African trypanosomiasisNECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sicknessGenotypic status of the TbAT1/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from Northwestern Uganda following melarsoprol withdrawalMathematical modelling of polyamine metabolism in bloodstream-form Trypanosoma brucei: an application to drug target identificationBenznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatmentsEliminating human African trypanosomiasis: where do we stand and what comes next?Exploiting the drug-activating properties of a novel trypanosomal nitroreductase.The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forwardEffectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.Incorporating scale dependence in disease burden estimates: the case of human African trypanosomiasis in UgandaThe human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.Treatment options for second-stage gambiense human African trypanosomiasis.New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289Trypanocidal drugs: mechanisms, resistance and new targets.Chemotherapy against human African trypanosomiasis: is there a road to success?Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis.The distribution of nifurtimox across the healthy and trypanosome-infected murine blood-brain and blood-cerebrospinal fluid barriersNifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein.Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis.Say what? The activity of the polyamine biosynthesis inhibitor difluoromethylornithine in chemoprevention is a result of reduced thymidine pools?Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.African sleeping sickness.Chemotherapy of human african trypanosomiasis.A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis
P2860
Q21144510-03CA7D9A-0B7C-4181-ACB5-2A418D596B61Q21198933-0E1D16F1-DC1D-4B76-BCD3-982DD5EC6F81Q26820381-199D1744-235C-4065-A689-79A3003ABF77Q28474074-940441C5-33AE-44F1-804E-280FDB543D3FQ28476222-F51A6F9D-ACB7-403F-A3D8-111432099DC3Q28485261-39BF76D6-A88C-4D0C-84F7-CE394200F6A6Q28535357-81F04D8A-619A-4E4E-B1EA-006F92B431D6Q33321396-CA0A8EEF-3E3A-42E7-9EF1-1CCA32D4D14DQ33520395-A49362FD-A28B-452C-A8EC-C9A6CFA3BB18Q33834072-ED5A6DF4-F62E-4C39-88B7-9D6E168E55C3Q34024866-2EAF42AF-6A71-40DB-B517-5C9EEAC7F0E5Q34500886-030C8007-7996-4DDC-AA37-63DC77011C46Q35097828-63BBB39A-A9D2-4716-8C9D-750C8AB0B90AQ36451580-98EB462E-8307-4C50-B88D-AD23CCDC6DF1Q36551049-82D07A25-53F3-4518-9C08-C97C391E54F0Q37392888-5691D335-8D10-45CD-80CC-7AF551A0FF59Q37623081-9FF35245-CDB1-4773-8015-0CF76E7D5E96Q37801690-122647E3-E060-4450-8F91-F4495194EBA3Q37981773-2EA60D46-B1CB-486B-B6D1-AFA26FB119F7Q38339557-CC8E8033-1175-4331-B720-15B6B2769DD2Q39223286-E6787E10-7310-4158-8520-E871933A8A7DQ39422104-C2B15F30-02AD-4E4C-8150-A93105DD772CQ39715299-2A415011-10F6-4054-A983-213508AC427EQ42085336-6ED1A51D-F542-47F1-855E-0C1EFA783B5DQ42421190-BCCC77B3-D632-44AD-A33C-4AAAEDD386B4Q43089194-FD76C2D4-6253-4B01-8028-FB192287181BQ52595328-51C2CD32-DD9D-44D6-873A-CBF55A4F1CE4Q52689446-E1A57FC1-ACC9-4FF7-BC81-5B6020AA879DQ56504613-A5ABD750-FDD0-4B78-913F-A81BD166ED87
P2860
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
@ast
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
@en
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
@nl
type
label
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
@ast
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
@en
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
@nl
prefLabel
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
@ast
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
@en
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
@nl
P2093
P2860
P921
P1476
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
@en
P2093
Dominique Legros
Florence Thomas
Francesco Checchi
Gerardo Priotto
Harriet Ayikoru
Patrice Piola
P2860
P356
10.1371/JOURNAL.PNTD.0000064
P407
P577
2007-11-07T00:00:00Z